Askari Biotechnology Ventures Ltd 12913028 false 2022-10-01 2023-09-30 2023-09-30 The principal activity of the company is Bio-tech Fertilizer and related products. Bird food Digita Accounts Production Advanced 6.30.9574.0 true 12913028 2022-10-01 2023-09-30 12913028 2023-09-30 12913028 core:RetainedEarningsAccumulatedLosses 2023-09-30 12913028 core:ShareCapital 2023-09-30 12913028 core:CurrentFinancialInstruments 2023-09-30 12913028 core:CurrentFinancialInstruments core:WithinOneYear 2023-09-30 12913028 bus:SmallEntities 2022-10-01 2023-09-30 12913028 bus:AuditExemptWithAccountantsReport 2022-10-01 2023-09-30 12913028 bus:FullAccounts 2022-10-01 2023-09-30 12913028 bus:SmallCompaniesRegimeForAccounts 2022-10-01 2023-09-30 12913028 bus:RegisteredOffice 2022-10-01 2023-09-30 12913028 bus:Director2 2022-10-01 2023-09-30 12913028 bus:PrivateLimitedCompanyLtd 2022-10-01 2023-09-30 12913028 countries:EnglandWales 2022-10-01 2023-09-30 12913028 2021-10-01 2022-09-30 12913028 2022-09-30 12913028 core:RetainedEarningsAccumulatedLosses 2022-09-30 12913028 core:ShareCapital 2022-09-30 12913028 core:CurrentFinancialInstruments 2022-09-30 12913028 core:CurrentFinancialInstruments core:WithinOneYear 2022-09-30 iso4217:GBP xbrli:pure

Registration number: 12913028

Askari Biotechnology Ventures Ltd

Annual Report and Unaudited Financial Statements- Companies house filing

for the Year Ended 30 September 2023

 

Askari Biotechnology Ventures Ltd

Contents

Statement of Financial Position

1

Notes to the Unaudited Financial Statements

2 to 3

 

Askari Biotechnology Ventures Ltd

(Registration number: 12913028)
Statement of Financial Position as at 30 September 2023

Note

2023
£

2022
£

Current assets

 

Debtors

4

197

297

Cash at bank and in hand

 

4,858

526

 

5,055

823

Creditors: Amounts falling due within one year

5

(25,241)

(17,839)

Net liabilities

 

(20,186)

(17,016)

Capital and reserves

 

Called up share capital

1

1

Profit and loss account

(20,187)

(17,017)

Shareholders' deficit

 

(20,186)

(17,016)

For the financial year ending 30 September 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Income Statement has been taken.

Approved and authorised by the Board on 9 February 2024 and signed on its behalf by:
 

.........................................
Mr B M Wood
Director

   
     
 

Askari Biotechnology Ventures Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 September 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is: Knoll House, Knoll Road, Camberley, Surrey, GU15 3SY, England.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Trade debtors

Short term debtors are measured at transaction price, less any impairment.

Cash and cash equivalents

Cash is represented by cash in hand and bank deposits.

Trade creditors

Short term creditors are measured at the transaction price.

Provisions

Provisions are recognised when the company has an obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

Employee benefits

Short-term employee benefits are recognised as an expense in the period which they are incurred.

Financial instruments

The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans to related parties.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2022 - 1).

 

Askari Biotechnology Ventures Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 September 2023

4

Debtors

2023
£

2022
£

Other debtors

133

80

Prepayments

64

217

197

297

5

Creditors

Creditors: amounts falling due within one year

2023
£

2022
£

Trade creditors

880

452

Accruals and deferred income

825

825

Other creditors

23,536

16,562

25,241

17,839

6

Going concern

The financial statements have been prepared on a going concern basis due to the continuing support of the director.